PURPOSE: Human papillomavirus type 16 (HPV-16) positivity is associated with favourable survival in oropharyngeal squamous cell carcinoma (OPSCC). We report here a study of the prognostic significance of (18)F-FDG PET/CT functional parameters and HPV-16 infection in OPSCC patients. METHODS: We retrospectively analysed 60 patients with stage III or IV OPSCC who had had a pretherapy (18)F-FDG PET/CT scan and had completed concurrent chemoradiotherapy (n = 58) or curative radiotherapy (n = 2). All patients were followed up for ≥24 months or until death. We determined total lesion glycolysis (TLG) and the maximal standardized uptake values (SUV(max)) of the primary tumour and neck lymph nodes from the pretherapy (18)F-FDG PET/CT scan. Optimal cut-offs of the (18)F-FDG PET/CT parameters were obtained by receiver operating characteristic (ROC) curve analyses. Pretherapy tumour biopsies were studied by polymerase chain reaction to determine HPV infection status. RESULTS: The pretherapy tumour biopsies were positive for HPV-16 in 12 patients (20.0 %). Cox regression analyses revealed HPV-16 positivity and tumour TLG >135.3 g to be independently associated with overall survival (p = 0.027 and 0.011, respectively). However, only tumour TLG >135.3 g was independently associated with progression-free survival, disease-free survival and locoregional control (p = 0.011, 0.001 and 0.034, respectively). A scoring system was formulated to define distinct overall survival groups using tumour TLG and HPV-16 status. Patients positive for HPV-16 and with tumour TLG ≤135.3 g experienced better survival than those with tumour TLG >135.3 g and no HPV infection (p = 0.001). CONCLUSION: Tumour TLG was an independent predictor of survival in patients with locally advanced OPSCC. A scoring system was developed and may serve as a risk stratification strategy for guiding therapy.
PURPOSE:Human papillomavirus type 16 (HPV-16) positivity is associated with favourable survival in oropharyngeal squamous cell carcinoma (OPSCC). We report here a study of the prognostic significance of (18)F-FDG PET/CT functional parameters and HPV-16infection in OPSCC patients. METHODS: We retrospectively analysed 60 patients with stage III or IV OPSCC who had had a pretherapy (18)F-FDG PET/CT scan and had completed concurrent chemoradiotherapy (n = 58) or curative radiotherapy (n = 2). All patients were followed up for ≥24 months or until death. We determined total lesion glycolysis (TLG) and the maximal standardized uptake values (SUV(max)) of the primary tumour and neck lymph nodes from the pretherapy (18)F-FDG PET/CT scan. Optimal cut-offs of the (18)F-FDG PET/CT parameters were obtained by receiver operating characteristic (ROC) curve analyses. Pretherapy tumour biopsies were studied by polymerase chain reaction to determine HPV infection status. RESULTS: The pretherapy tumour biopsies were positive for HPV-16 in 12 patients (20.0 %). Cox regression analyses revealed HPV-16 positivity and tumourTLG >135.3 g to be independently associated with overall survival (p = 0.027 and 0.011, respectively). However, only tumourTLG >135.3 g was independently associated with progression-free survival, disease-free survival and locoregional control (p = 0.011, 0.001 and 0.034, respectively). A scoring system was formulated to define distinct overall survival groups using tumourTLG and HPV-16 status. Patients positive for HPV-16 and with tumourTLG ≤135.3 g experienced better survival than those with tumourTLG >135.3 g and no HPV infection (p = 0.001). CONCLUSION:TumourTLG was an independent predictor of survival in patients with locally advanced OPSCC. A scoring system was developed and may serve as a risk stratification strategy for guiding therapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Steven H Lin; Ritsuko Komaki; Zhongxing Liao; Caimiao Wei; Bevan Myles; Xiaomao Guo; Matthew Palmer; Radhe Mohan; Stephen G Swisher; Wayne L Hofstetter; Jaffer A Ajani; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-13 Impact factor: 7.038
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Jose G Guillem; Harvey G Moore; Timothy Akhurst; David S Klimstra; Leyo Ruo; Madhu Mazumdar; Bruce D Minsky; Leonard Saltz; W Douglas Wong; Steven Larson Journal: J Am Coll Surg Date: 2004-07 Impact factor: 6.113
Authors: Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani Journal: Eur J Nucl Med Mol Imaging Date: 2016-01-19 Impact factor: 9.236
Authors: Thong Chotchutipan; Benjamin S Rosen; Peter G Hawkins; Jae Y Lee; Anjali L Saripalli; Dharmesh Thakkar; Avraham Eisbruch; Issam El Naqa; Michelle L Mierzwa Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: T J Rath; S Narayanan; M A Hughes; R L Ferris; S I Chiosea; B F Branstetter Journal: AJNR Am J Neuroradiol Date: 2017-04-27 Impact factor: 3.825